

# Adherence of Patients with Coronary Heart Disease to Treatment Plan and its relation with HRQL

Manal Ibrahim Hanafi Mahmoud<sup>1,2</sup>, Ahmed Hassan Alrefaei<sup>1\*</sup>, Abdulrahman Mohammed Aljabri<sup>1</sup>, Sultan Mohammed Algarni<sup>1</sup>, Abdullah Hamdan Alorabi<sup>1</sup>, Ahmad Mohammad Khaled Kouki<sup>1</sup>, Asmaa Abdelnasser<sup>1,3</sup>

<sup>1</sup>Ibn Sina National College for Medical Studies, Jeddah, KSA. <sup>2</sup>Faculty of Medicine, Alexandria University, Alexandria, Egypt. <sup>3</sup>Faculty of Medicine, Suez Canal University, Alsmailia, Egypt.

## Abstract

Coronary artery disease is a leading cause of morbidity and mortality worldwide. Its management involves a combination of lifestyle modifications and medical interventions. However, the effectiveness of treatments is highly dependent on patient adherence to the prescribed treatment regimen. To explore the adherence level of patients with coronary heart disease to treatment regimen, identify factors affecting adherence, determine health-related quality of life, and measure the relationship between adherence of coronary heart disease patients to treatment regimen and health-related quality of life. Cross-sectional study was conducted in outpatient cardiology clinics of three private hospitals in Jeddah City including 222 coronary patients under treatment. An interview format, pre-coded, pilot tested was used. Arabic version of the RAND 36-item health survey was used. 43.2% of patients followed multiple treatment plans ( $p=0.000$ ). 73.9% of patients insignificantly had comorbid conditions. Factors that significantly affected adherence to the treatment plan were availability of medications ( $p=0.02$ ), side effects of medications ( $p=0.001$ ), patient-physician relationship ( $p=0.002$ ), development of complication ( $p=0.001$ ), follow-up schedule ( $p=0.000$ ), continuous health education ( $p=0.000$ ). There was a significant difference between non-adherent and adherent groups for all scales of the RAND 36-item health survey. The significant predictors include work status, the treatment plan, and associated comorbid conditions. More than half of CAD patients were non-adherent to their treatment regimen. Factors affecting adherence level include availability, side effects, development of complications, cost of medications, and patient-physician relationship.

**Keywords:** Adherence to treatment, Coronary artery disease, Quality of life, RAND questionnaire

## INTRODUCTION

Heart diseases, particularly Coronary Artery Disease (CAD), are prevalent life-threatening causes of morbidity and mortality worldwide [1]. CAD is the third cause of leading mortality worldwide [2]. In order to minimize the disease's complications potential, prevent comorbidities, improve the quality of life, and minimize the damage the disease is putting on the individuals, the management plan of CAD is tailored to involve a combination of lifestyle modifications; mainly dietary modification and exercises together with medical interventions [3]. However, the effectiveness and success of the treatment plan are highly dependent on patient adherence to the prescribed regimen [3].

Several studies have investigated the impact of patient adherence on the health-related quality of life (HRQoL) in individuals with CAD [4, 5]. Furthermore, studies carried out in Saudi Arabia [5, 6] explored the factors influencing patient adherence to treatment in (CAD). The findings indicated that patient education, social support, patient-physician relationship, and communication patterns played crucial roles in promoting adherence [5, 6]. On the other hand, barriers such as medication side effects, forgetfulness, and lack of understanding about the importance of adherence were identified as factors contributing to non-adherence [6].

Moreover, many researches emphasized the role of psychosocial factors, such as social support and depression, in mediating the relationship between adherence and HRQoL [7, 8].

The higher the number of medications prescribed along with regimens, the more complicated the medication regimen, and the higher the cost of medication, the higher the risk of poor adherence. This was also proved in one study that was carried out in KSA [9]. The RAND 36-item health survey is among the most widely used instruments to assess the quality of life

**Address for correspondence:** Ahmed Hassan Alrefaei, Ibn Sina National College for Medical Studies, Jeddah, KSA. aahmed28900@gmail.com

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non commercially, as long as the author is credited and the new creations are licensed under the identical terms.

**How to cite this article:** Hanafi Mahmoud MI, Alrefaei AH, Aljabri AM, Algarni SM, Alorabi AH, Kouki AMK, et al. Adherence of Patients with Coronary Heart Disease to Treatment Plan and its relation with HRQL. Arch Pharm Pract. 2023;14(S):A06231502.

in chronically ill individuals [10]. Its validity, reliability, and responsiveness have been documented across various groups, including those differing in age, sex, socio-economic status, geographical region, and clinical conditions [11].

Understanding the impact of patient adherence on health-related quality of life is essential for optimizing the management of coronary artery disease [12]. Nevertheless, it is mandatory to assess the treatment plan in conjunction with patients' adherence to this plan, concomitant with the assessment of their impact on HRQoL [12]. Therefore, this research will be conducted to explore this relationship and identify the influencing factors affecting adherence to treatment and quality of life, our research objectives were to explore the adherence level of patients with coronary heart disease to their treatment regimen, to identify factors affecting adherence of patients with coronary heart disease to their treatment regimen, to determine the health-related quality of life among patients with coronary heart disease under treatment and measure the relationship between adherence of coronary heart disease patients to treatment regimen and health-related quality of life.

## MATERIALS AND METHODS

### Study Setting and Population

A cross-sectional study design with a case-control approach was carried out in the outpatient cardiology clinics of three private hospitals in Jeddah City.

### Sample Size and Technique

The total number of patients to be selected was estimated using the following formula: [13]

$$n_0 = Z^2 pq / e^2 \quad (1)$$

Where; Z = critical value of the desired confidence interval (1.96 at 95%, 1.645 at 90%, 2.33 at 98%, and 2.575% at 99%) e= margin of error; 0.05 p= the estimated proportion of attribute that is present in the population; 0.50, q= 1-p; 0.50. Using this formula, the inclusion of a convenient, non-probability sample of about 222 patients with coronary heart disease under treatment was carried out during their follow-up visits to the outpatient clinics of the allocated hospitals.

### Study Instrument

An interview specially prepared format in English and Arabic which is closed-ended, pre-coded, and pilot tested was used. Training of the data collectors on the use of this format was carried out. It included sociodemographic data, and information about the CAD patients' adherence to diet, exercise, and medications.

An Arabic version of the RAND health survey which is a standardized questionnaire for assessment of quality of life was also used. RAND 36-Item Health Survey is a generic

questionnaire that measures eight health-related domains namely physical functioning (includes 10 items), role-physical (role limitations due to physical impairments, includes 4 items), bodily pain (includes 2 items), role-emotional (role limitations due to personal or emotional problems, include 3 items), emotional wellbeing (including 5 items), social functioning (include 2 items), vitality/fatigue (include 3 items), and general health (include 5 items). Higher scores represent more favorable health status [14].

### Ethical Approval

The Ethical clearance for the study was obtained from the Ibn Sina National College Research and Ethics Committee (IRRB-01-01102023). Informed written consent was obtained from each participant before being included in the study. Privacy and confidentiality of participants and their data were assured. Ethical conduct was maintained during data collection and throughout the research process in accordance with the Helsinki Declaration [15].

### Inclusion Criteria

Male or female patients with coronary heart disease under treatment attending the cardiology outpatient clinics of the three allocated private hospitals in Jeddah.

### Exclusion Criteria

Patients without coronary heart disease, untreated coronary artery disease patients, and those with any psychiatric or memory problems.

### Statistical Analysis

Data will be collected and coded before being entered into the Statistical Package for Social Sciences version 22 (SPSS Inc., Chicago, IL, USA). Descriptive statistics will be carried out for all variables. A suitable test of significance will be used. A P-value less than 0.05 will considered to be significant. Determination of the predictors affecting RAND domains will be determined using linear regression. Calculation of adherence score was done with the division of the sample according to adherence level into **Non-Adherent** (with a score of less than 60%) and **Adherent** (with a score of more than 60%). The percent scores for adherence were calculated using the following formula:

$$\text{Percent score} = \frac{\sum \text{Scores of questions selected}}{\text{maximum possible score for these questions}} \times 100 \quad (2)$$

## RESULTS AND DISCUSSION

This study included 222 coronary artery disease patients under treatment recruited from outpatient clinics of three private hospitals in Jeddah, KSA during their follow-up visits. The mean age in years of the adherent patients to the treatment plan was significantly younger than the non-adherent group [mean= 57.6 (8.06), 61.8 (7.06) respectively; p=0.000]. More than three-fourths (79.3%) of the studied patients were males (p=0.032), 81.1% were insignificantly

married, 55.0% were insignificantly working, and 51.4% were ever-smokers (p=0.046). The mean duration of coronary artery disease in years was significantly lower [5.2 (3.23; p= 0.008]. Less than half (43.2%) of the studied patients significantly followed multiple treatment plans like

medications, diet, and exercise (p=0.000). Nearly three-fourths (73.9%) of the studied patients insignificantly had comorbid conditions; mainly diabetes mellitus and hypertension (**Table 1**).

**Table 1.** General Description of the study population by their adherence level

	Non-adherent group		Adherent group		Total		p-value
	N=118	%	N=104	%	N=222	%	
<b>Age in years</b>							
Mean (Sd)	61.8 (7.06)		57.6 (8.06)		59.8 (7.82)		0.000*
<b>Gender</b>							
Male	100	84.7	76	73.1	176	79.3	0.032*
Female	18	15.3	28	26.9	46	20.7	
<b>Education</b>							
Basic	16	13.6	20	19.2	36	16.2	0.253
Secondary and more	102	86.4	84	80.8	186	83.8	
<b>Marital Status</b>							
Never married	28	23.7	14	13.5	42	18.9	0.051
Ever married	90	76.3	90	86.5	180	81.1	
<b>Work status</b>							
Not working	60	50.8	40	38.5	100	45.0	0.064
Working	58	49.2	64	61.5	122	55.0	
<b>Smoking history</b>							
Never smoke	50	42.4	58	55.8	108	48.6	0.046*
Ever smoke	68	57.6	46	44.2	114	51.4	
<b>CAD** duration in years</b>							
Mean (Sd)	6.4 (3.59)		5.2 (3.23)		5.8 (3.47)		0.008*
<b>Treatment plan</b>							
Single plan	86	72.9	40	38.5	126	56.8	0.000*
Multiple plans	32	27.1	65	61.5	97	43.2	
<b>Self-reported response</b>							
Not responding	26	22.0	4	3.8	30	13.5	0.000#
Responding	92	78.0	100	96.2	192	86.5	
<b>Comorbid conditions&amp;</b>							
No	26	22.0	32	30.8	58	26.1	0.139
Yes	92	78.0	72	69.2	164	73.9	

\*p-value is significant at <0.05 level

#Fisher Exact Test

\*\*CAD=Coronary artery disease

&= mainly Diabetes mellitus and hypertension

Factors that significantly affected the adherence of patients to the treatment plan were availability of medications (p=0.02), side effects of medications (p=0.001), patient-physician relationship (p=0.002), development of complications (p=0.001), the follow-up schedule (p=0.000). They also

included continuous health education (p=0.000), omitting medication (p=0.000), difficult change of dietary habits (p=0.000), and non-convenient with the effect of exercise (p= 0.000) (**Table 2**).

**Table 2.** Factors affecting adherence to the treatment plan according to CAD patients' point of view

	Non-adherent group		Adherent group		Total		p-value
	N=118	%	N=104	%	N=222	%	
<b>Availability of medication</b>							
No	6	5.1	0	0.0	6	2.7	0.020#
Yes	112	94.9	104	100.0	216	97.3	
<b>Cost of medication</b>							
No	52	44.1	50	48.1	102	45.9	0.550
Yes	66	55.9	54	51.9	120	54.1	
<b>Side effects of medications</b>							

No	90	76.3	96	92.3	186	83.8	0.001*
Yes	28	23.7	8	6.7	36	16.2	
<b>Patient-physician relationship</b>							
No	16	13.6	2	1.9	18	8.1	
Yes	102	86.4	102	98.1	204	91.9	0.002#
<b>Development of complication</b>							
No	86	72.9	94	90.4	180	81.1	0.001*
Yes	32	27.1	10	9.6	42	18.9	
<b>The follow up schedule</b>							
No	76	64.4	12	11.5	88	39.6	0.000*
Yes	42	35.6	92	88.5	134	60.4	
<b>Continuous health education</b>							
No	78	66.1	32	30.8	110	49.5	
Yes	40	33.9	72	69.2	112	50.5	0.000*
<b>Omitting medication due to forgetting their intake</b>							
No	20	16.9	48	46.2	68	30.6	0.000*
Yes	98	83.1	56	53.8	154	69.4	
<b>Difficult changing habits</b>							
No	14	11.9	36	34.6	50	22.5	0.000*
Yes	104	88.1	68	65.4	172	77.5	
<b>Non-convenient with the effect of exercise</b>							
No	76	64.4	100	96.2	176	79.3	
Yes	42	35.6	4	3.8	46	20.7	0.000#

#Fisher Exact Test

\*p-value is significant at <0.05 level

**Table 3** illustrates that there was a significant difference between non-adherent and adherent groups for all scales of the RAND 36-item health survey; namely physical functioning (p=0.000), role limitations due to physical health (p=0.000), role limitations due to emotional problems (p=0.11), energy (p=0.000), emotional wellbeing (p=0.11), social functioning (p=0.005), pain (p=0.000) and general health (p=0.007) (**Table 3**).

**Table 3.** Distribution of the scales of RAND 36-item Health survey and adherence level

	Non-adherent group	Adherent group	Total	p-value
<b>Physical functioning</b>				
Mean (Sd)	57.5 (21.35)	80.7 (16.43)	68.3 (22.40)	0.000*
<b>Role limitations due to physical health</b>				
Mean (Sd)	27.5 (16.6)	70.7 (15.43)	47.7 (11.94)	0.000*
<b>Role limitations due to emotional problems</b>				
Mean (Sd)	44.1 (2.89)	34.9 (3.42)	61.0 (3.22)	0.000*
<b>Energy/fatigue</b>				
Mean (Sd)	45.7 (1.67)	64.9 (6.47)	54.7 (9.35)	0.000*
<b>Emotional well-being</b>				
Mean (Sd)	53.5 (9.19)	69.3 (15.88)	60.9 (19.7)	0.011*
<b>Social functioning</b>				
Mean (Sd)	58.5 (9.18)	81.3 (12.51)	69.14 (18.58)	0.005*
<b>Pain</b>				
Mean (Sd)	69.5 (2.13)	89.3 (4.62)	78.8 (2.37)	0.000*
<b>General health</b>				
Mean (Sd)	44.3 (7.36)	62.6 (4.93)	52.9 (8.62)	0.007*

\*p-value is significant at <0.05 level

Collectively, the significant predictors of the eight scales of the RAND 36-item health survey among coronary artery disease patients were age, marital status, work status, duration of coronary heart disease, the treatment plan, associated comorbid conditions, and gender (**Table 4**).

**Table 4.** Multiple linear regression model for the Relation between RAND 36-item Health Survey scales and CAD patients' attributes (Only significant predictors are presented in the table)

Scale	Attribute	R <sup>2</sup>	β	Sig.	95%CI for β	
					Lower bound	Upper bound
<b>Physical functioning</b>	Age	.137	-.371	.000*	-1.416	-.709
	Marital status	.047	.261	.001*	4.929	19.736
	Work status	.062	.248	.000*	5.378	16.943
	Duration of CAD	.075	-.274	.000*	-2.597	-.946
	Treatment plan	.125	.354	.000*	10.360	21.575
<b>Role limitations due to physical health</b>	Co-morbid conditions	.030	-.173	.001*	-15.450	-2.132
	Age	.210	-.458	.000*	-3.092	-1.824
	Marital status	.023	.153	.023	2.277	30.342
	Work status	.131	.362	.000*	20.057	40.893
	Duration of CAD	.113	-.336	.000*	-5.572	-2.544
<b>Role limitations due to emotional problems</b>	Treatment plan	.095	.308	.000*	15.311	36.673
	Co-morbid conditions	.041	-.203	.002*	-31.780	-6.993
	Age	.180	-.425	.000*	-3.013	-1.683
	Work status	.127	.356	.000*	20.103	41.624
	Duration of CAD	.158	-.397	.000*	-6.470	-3.431
<b>Energy/fatigue</b>	Treatment plan	.146	.383	.001*	22.615	43.985
	Co-morbid conditions	.049	-.221	.000*	-34.445	-9.009
	Age	.063	-.250	.000*	-1.048	-.337
	Work status	.101	.318	.000*	8.340	19.264
	Duration of CAD	.131	-.362	.000*	-3.028	-1.483
<b>Emotional well-being</b>	Treatment plan	.056	.236	.000*	4.660	15.905
	Co-morbid conditions	.123	-.351	.000*	-23.341	-11.121
	Marital Status	.051	.226	.001*	4.782	17.554
	Duration of CAD	.066	-.258	.000*	-2.157	-.723
	Treatment plan	.053	.230	.001*	3.930	14.018
<b>Social functioning</b>	Co-morbid conditions	.062	-.249	.000*	-16.626	-5.305
	Age	.090	-.300	.000*	-1.561	-.634
	Education	.028	.167	.013*	2.768	23.023
	Marital status	.023	.153	.023*	1.571	20.691
	Work status	.084	.290	.000*	9.352	23.927
<b>Pain</b>	Duration of CAD	.108	-.329	.000*	-3.744	-1.676
	Treatment plan	.115	.339	.000*	12.298	26.690
	Co-morbid conditions	.091	-.302	.000*	-27.818	-11.374
	Age	.351	-.315	.000*	-1.206	-.517
	Marital status	.020	.142	.035*	.561	14.883
<b>General health</b>	Work status	.074	.272	.000*	6.187	17.146
	Duration of CAD	.122	-.350	.000*	-2.921	-1.387
	Treatment plan	.079	.281	.000*	6.604	17.582
	Co-morbid conditions	.109	-.330	.000*	-22.118	-9.943
	Age	.035	-.187	.005*	-.757	-.135
<b>General health</b>	Marital status	.024	.155	.021*	1.146	13.600
	Work status	.034	.184	.006*	2.006	11.761
	Duration of CAD	.046	-.215	.001*	-1.854	-.460
	Treatment plan	.056	.236	.000*	4.027	13.711
	Co-morbid conditions	.057	-.239	.000*	-15.558	-4.643

\*p-value is significant at <0.05 level

A cross-sectional study was carried out involving 222 patients with CAD under treatment during their follow-up

visits to cardiology outpatient clinics of three private hospitals in Jeddah, KSA. The study aimed to explore the

adherence level of patients with coronary heart disease to their treatment regimens, identify factors affecting their adherence, determine the health-related quality of life among patients with coronary heart disease under treatment, and measure the relationship between adherence to coronary heart disease patients to treatment regimen and health-related quality of life. It was planned to achieve these objectives through the use of a specially prepared pilot-tested interview format together with an Arabic version of the RAND 36-Item Health Survey.

The present study revealed that 53.2% of the examined patients were non-adherent to their treatment regimen. One of the factors influencing adherence levels was the availability of medications, a finding supported by Veronika J. Wirts *et al.* in 2016 and Muhammad Jami Husain *et al.* in 2020 [16]. The cost of medication plays a crucial role in the adherence to treatment regimens for various diseases, including coronary heart disease. The current study found that 54.1% of the participants reported the insignificance of treatment cost on adherence levels. Similar research has shown a threefold increase in the rate of non-adherence, particularly among the elderly and women with low socio-economic standards [17]. A systematic review [17] indicated that 82% of its included studies found a significant association between high medication costs and non-adherence.

The side effects of coronary heart disease, whether stemming from the disease process itself or its medications, are significant contributors to discontinuation and non-adherence to the treatment plan [18, 19]. However, nearly one-fourth of our non-adherent group identified the development of medication side effects or disease complications as important causes for non-adherence.

A crucial factor for adherence and commitment to the treatment plan and follow-up visits is the patient-physician relationship, coupled with continuous health education. The majority of the studied patients in the present work significantly stated that a good patient-physician relationship, along with continuous health education, has an obvious effect on their commitment to follow-up visits, a finding consistent with similar studies [19, 20]. Physicians with effective consultation and communication skills can attract and motivate their patients for better compliance [19].

The present study revealed a significantly higher rate of non-adherence among the elderly, males, those with a longer duration of illness, and individuals with associated co-morbid conditions. Similar findings have been reported in other studies and are often explained by the possibility of reluctant behavior, a trait influenced by various environmental factors, including sociodemographic factors such as gender, marital status, duration of illness, and the presence of other co-morbid conditions. This behavior can impact the commitment to the treatment regimen in general and, specifically, adherence to dietary regimens and exercises [21, 22].

Furthermore, patient age plays a crucial role in memory impairment, affecting their ability to adhere to medication schedules. A previous study indicated that 84.9% of the studied population exhibited non-adherence to cardiovascular medications due to forgetfulness [22].

In coronary heart disease, adherence to the treatment regimen has implications for the quality of life. A study demonstrated that non-adherence is correlated with lower scores on the quality-of-life scales, particularly the physical functioning scale of the RAND 36-item health survey [23]. Similar conclusions were drawn in our research, where adherence levels significantly affected all scales, including the physical functioning scale.

A study conducted in Saudi Arabia in 2022 [24] found that chronic diseases, including coronary artery disease (CAD), are associated with lower quality of life scales due to their chronic nature, resulting in limitations, a multitude of symptoms, and polypharmacy with associated side effects. These effects are further exacerbated when there are additional co-morbid conditions [25].

Hence, coronary artery disease is a multifactorial illness, and interpreting the quality of life in its patients is a complex task [26]. Most previous studies have characterized health-related quality of life assessment as a subjective tool because of the self-reported nature of the data, which is based on patients' perceptions of their condition [27, 28]. Nevertheless, Alla *et al.* [29] and Scott *et al.* [30] eventually agreed on a multidimensional account that encompasses the physical, psychological, and social dimensions of HRQoL, as incorporated in the RAND-36 item health survey [31-33]. Therefore, the present study found higher scores for the RAND scales compared to previous studies in the KSA's Eastern region [34], Ethiopia [35], and Spain [36]. This might be explained by methodological differences, variations in the history of comorbidities, duration of the disease, treatment regimen, and adherence level.

In the present study, the lowest scores were observed for the role limitations due to the physical functioning scale, consistent with a study conducted in Spain [36] that indicated coronary artery disease (CAD) patients experience physical symptoms adversely affecting their ability to perform daily life activities [37]. The present study found that the highest scores were for the social functioning and bodily pain scales, aligning with a study in Spain [36]. These findings suggest that CAD patients may attempt to maintain a positive psychosocial attitude despite physical limitations in their daily activities, positively impacting their health-related quality of life [31]. For patients in Saudi Arabia, the availability of personal attendants and family members for religious and sociocultural reasons may also be important contributory factors [35].

The present work demonstrates that the treatment plan is the most significant attribute affecting physical and social functioning scales, while work status is the most significant one for both role limitations due to physical health and emotional problems. The presence of associated co-morbid conditions is an important significant attribute of the energy/fatigue scale.

## CONCLUSION

The present study concludes that more than half of coronary artery disease (CAD) patients were non-adherent to their treatment regimens. Factors influencing adherence levels included the availability of medications, side effects, development of complications, medication costs, and the patient-physician relationship. Regarding the RAND 36-item health survey, the highest scores were observed for pain, social functioning, and physical functioning, while the lowest scores were for role limitations due to physical health and general health. The most significant attributes affecting the RAND 36-item health survey were the treatment plan, work status, and associated co-morbid conditions.

## Recommendation

Emphasis should be placed on the development of a strong physician-patient relationship and the enhancement of physicians' communication skills, as they play a key role in delivering health education to patients. This, in turn, has a significant impact on patients' adherence to treatment plans and scheduled follow-ups. Achieving this goal involves continuous training for physicians and ongoing assessment of patient satisfaction. Additionally, there should be careful planning of health education tools and materials aimed at educating patients about the importance of adherence to all aspects of their treatment plans and the positive correlation between adherence levels and the improvement of quality of life.

## Study Limitations

The main constraints identified in this study include limitations related to study design and sampling technique. Additionally, the absence of a comparison group, particularly from public hospitals, and the lack of patient follow-up were notable limitations.

**ACKNOWLEDGMENTS:** Great thanks to all the patients who participated and shared their experiences with us. We extend our appreciation to all the medical directors who facilitated the process of data collection from the participants.

**CONFLICT OF INTEREST:** None

**FINANCIAL SUPPORT:** None

**ETHICS STATEMENT:** The Ethical clearance for the study was obtained from the Ibn Sina National College Research and Ethics Committee (IRRB-01-01102023). Informed written consent was obtained from each participant before being included in the study. Privacy and confidentiality of participants and their data were assured. Ethical conduct was

maintained during data collection and throughout the research process in accordance with the Helsinki Declaration.

## REFERENCES

1. Celermajer DS, Chow CK, Marijon E, Anstey NM, Woo KS. Cardiovascular disease in the developing world: prevalences, patterns, and the potential of early disease detection. *J Am Coll Cardiol*. 2012;60(14):1207-16.
2. Ford TJ, Berry C. How to diagnose and manage angina without obstructive coronary artery disease: lessons from the British Heart Foundation CorMicA trial. *Int Cardiol Rev*. 2019;14(2):76.
3. Lee YM, Kim RB, Lee HJ, Kim K, Shin MH, Park HK, et al. Relationships among medication adherence, lifestyle modification, and health-related quality of life in patients with acute myocardial infarction: a cross-sectional study. *Health Qual Life Outcomes*. 2018;16:1-8.
4. Clemens A, Vogelmeier C, Greulich T, Marin JM, Castellani W, Similowski T, et al. Top-10 comorbidities of symptomatic patients with moderate COPD in the clinical setting of the CRYSTAL study. *Eur Respir J*. 2016;48(Issue suppl 60).
5. Staniute M, Brozaitiene J, Bunevicius R. Effects of social support and stressful life events on health-related quality of life in coronary artery disease patients. *J Cardiovasc Nurs*. 2013;28(1):83-9.
6. Suhail M, Saeed H, Saleem Z, Younas S, Hashmi FK, Rasool F, et al. Association of health literacy and medication adherence with health-related quality of life (HRQoL) in patients with ischemic heart disease. *Health Qual Life Outcomes*. 2021;19(1):1-13.
7. Silavanich V, Nathisuwan S, Phrommintikul A, Permsuwan U. Relationship of medication adherence and quality of life among heart failure patients. *Heart Lung*. 2019;48(2):105-10.
8. Thomson P, Rushworth GF, Andreis F, Angus NJ, Mohan AR, Leslie SJ. Longitudinal study of the relationship between patients' medication adherence and quality of life outcomes and illness perceptions and beliefs about cardiac rehabilitation. *BMC Cardiovasc Disord*. 2020;20(1):1-11.
9. Fallatah MS, Alghamdi GS, Alzahrani AA, Sadagah MM, Alkharji TM. Insights Into Medication Adherence Among Patients With Chronic Diseases in Jeddah, Saudi Arabia: A Cross-Sectional Study. *Cureus*. 2023;15(4).
10. Pappa E, Kontodimopoulos N, Niakas D. Validating and norming of the Greek SF-36 Health Survey. *Qual Life Res*. 2005;14:1433-8.
11. Je W. SF-36 health survey. Manual and interpretation guide. Boston: The Health Institute, New England Medical Center. 1993:10-6.
12. Stafford L, Berk M, Reddy P, Jackson HJ. Comorbid depression and health-related quality of life in patients with coronary artery disease. *J Psychosom Res*. 2007;62(4):401-10.
13. Daniel WW, Cross CL. Biostatistics: a foundation for analysis in the health sciences. Wiley. 2018.
14. Wilson RW, Hutson LM, VanStry D. Comparison of 2 quality-of-life questionnaires in women treated for breast cancer: The RAND 36-item health survey and the Functional Living Index-Cancer. *Phys Ther*. 2005;85(9):851-60.
15. WMA, The World Medical Association-WMA Declaration of helsinki – ethical principles for medical research involving human subjects [Internet]. [cited 2023 Nov 25]. Available from: <https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>
16. World Health Organization. Cardiovascular diseases (CVDs) key facts. 2020.
17. Husain MJ, Datta BK, Kostova D, Joseph KT, Asma S, Richter P, et al. Access to cardiovascular disease and hypertension medicines in developing countries: an analysis of essential medicine lists, price, availability, and affordability. *J Am Heart Assoc*. 2020;9(9):e015302.
18. Guthrie R. Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events. *Adv Ther*. 2011;28(6):473-82.
19. Wroth TH, Pathman DE. Primary medication adherence in a rural population: the role of the patient-physician relationship and satisfaction with care. *J Am Board Fam Med*. 2006;19(5):478-86.

20. Beach MC, Keruly J, Moore RD. Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV?. *J Gen Intern Med.* 2006;21:661-5.
21. Siddiqi K, Dogar OF, Siddiqi N. Smoking cessation in long-term conditions: is there "an opportunity in every difficulty". *Int J Popul Res.* 2013;2013(10):251048.
22. Khatib R, Marshall K, Silcock J, Forrest C, Hall AS. Adherence to coronary artery disease secondary prevention medicines: exploring modifiable barriers. *Open Heart.* 2019;6(2):e000997.
23. Peacock E, Joyce C, Craig LS, Lenane Z, Holt EW, Muntner P, et al. Low medication adherence is associated with decline in health-related quality of life: results of a longitudinal analysis among older women and men with hypertension. *J Hypertens.* 2021;39(1):153.
24. Alharbi M, Alharbi F, AlTuwayjiri A, Alharbi Y, Alhofair Y, Alanazi A, et al. Assessment of health-related quality of life in patients with heart failure: a cross-sectional study in Saudi Arabia. *Health Qual Life Outcomes.* 2022;20(1):1-7.
25. Roger VL. Epidemiology of heart failure. *Circ Res.* 2013;113(6):646-59.
26. Riedinger MS, Dracup KA, Brecht ML, Investigators SOLVD. Quality of life in women with heart failure, normative groups, and patients with other chronic conditions. *Am J Crit Care.* 2002;327(3):211-9.
27. Sneed NV, Paul S, Michel Y, VanBakel A, Hendrix G. Evaluation of 3 quality of life measurement tools in patients with chronic heart failure. *Heart Lung.* 2001;30(5):332-40.
28. Alla F, Briançon S, Guillemin F, Juillièrè Y, Mertès PM, Villemot JP, et al. Self-rating of quality of life provides additional prognostic information in heart failure. Insights into the EPICAL study. *Eur J Heart Fail.* 2002;4(3):337-43.
29. Scott LD. Caregiving and care receiving among a technologically dependent heart failure population. *Adv Nurs Sci.* 2000;23(2):82-97.
30. Ware JE Jr, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection author (s). *Med Care.* 1992;30(6):473-83.
31. Gandek B, Sinclair SJ, Kosinski M, Ware JE Jr. Psychometric evaluation of the SF-36® health survey in medicare managed care. *Health Care Financ Rev.* 2004;25(4):5.
32. Brazier JE, Harper R, Jones NM, O'cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. *BMJ.* 1992;305(6846):160-4.
33. AbuRuz ME, Alaloul F, Saifan A, Masa'Deh R, Abusalem S. Quality of life for Saudi patients with heart failure: a cross-sectional correlational study. *Global J Health Sci.* 2016;8(3):49.
34. Tarekegn GE, Gezie LD, Birhan TY, Ewnetu F. Health-related quality of life among heart failure patients attending an outpatient clinic in the University of Gondar Comprehensive Specialized Hospital Northwest, Ethiopia, 2020: using structural equation modeling approach. *Patient Relat Outcome Meas.* 2021;12:279.
35. Rodríguez-Artalejo F, Guallar-Castillón P, Pascual CR, Otero CM, Montes AO, García AN, et al. Health-related quality of life as a predictor of hospital readmission and death among patients with heart failure. *Arch Intern Med.* 2005;165(11):1274-9.
36. Lainscak M, Keber I. Patient's view of heart failure: from the understanding to the quality of life. *Eur J Cardiovasc Nurs.* 2003;2(4):275-81.
37. Schiff GD, Fung S, Speroff T, McNutt RA. Decompensated heart failure: symptoms, patterns of onset, and contributing factors. *Am J Med.* 2003;114(8):625-30.